Alle afleveringen
494 afleveringen, van nieuw naar oud
-
ASCO 2025: PharmaMar presented data showing that the combo of Zepzelca and Tecentriq significantly improved survival as first-line maintenance therapy for extensive-stage small cell lung cancer
3 juni 2025 · 12 min
Global Product Lead José Antonio López-Vilariño describes the data and VP of Strategic Development Pascal Besman puts the result in context of this cancer type and stage that historically has had a very poor prognosis.
-
ASCO 2025: France based Transgene presented data for its personalized cancer vaccine in the adjuvant setting for HPV- head and neck cancer
3 juni 2025 · 14 min
Chairman and CEO Alessandro Riva describes the computational work that is done to choose the personalized neoantigens for this cancer vaccine, and he describes why head and neck was a good fit to test the therapy out in. Plus, he covers the data and talks about next steps. Lees meer
-
ASCO 2025: Candel Therapeutics CEO Paul Peter Tak describes phase 3 prostate cancer data from the company's off-the-shelf, adeno delivered, cancer immunotherapy
3 juni 2025 · 16 min
He explains the design of the therapy, and covers the data presented at ASCO. Plus, filing and manufacturing plans, and highlighting this program in other cancers.
-
ASCO 2025: Strand Therapeutics Co-Founder & CEO Jake Becraft discusses the clinical data presentation for the company's IL-12, self-replicating mRNA cancer immunotherapy
3 juni 2025 · 10 min
He explains why IL-12, and how the self-replicating aspect may be giving this more durability over first generation mRNA cancer immunotherapies. He covers the data, and describes how Strand is seeing the abscopal effect in some patients for this intra-tumoral administered product. Lees meer
-
ASCO 2025: Allogene presented data today for a CD70 targeting allogeneic CAR-T against renal cell carcinoma, with a 31% response rate
2 juni 2025 · 14 min
CEO David Chang\ describes the data and explains why he believes the company's "Dagger" platform makes a difference. Plus, an update on Allogene's 1L consolidation trial in LBCL, and his thoughts on cell therapy for autoimmune diseases.
-
ASCO 2025: The leaders of Daiichi-Sankyo discuss new data for the ADC ENHERTU in 1L HER2+ breast cancer and 2L HER2+ gastric cancer, plus new targets that are emerging
2 juni 2025 · 15 min
Global Head of Oncology Ken Keller walks us through the company's ASCO data and highlights other future catalysts to watch, which new Global CEO Hiroyuki Okuzawa discusses the company's long-term plans to be a top 10 oncology company.
-
Deerfield Management Managing Partner James Flynn discusses a new $600M venture fund the firm has raised and describes how it will be invested, including into AI companies
2 juni 2025 · 12 min
He describes raising the fund, and his take on the current challenging environment in healthcare. Plus, his thoughts on AI specifically, and how Deerfield is adding new people to both participate in it and invest in it.
-
ASCO 2025: Protagonist Therapeutics' CEO Dinesh Patel discusses the results of the phase 3 study of Rusfertide for polycythemia vera, plus a recap of recent ulcerative colitis data for its IL-23R
2 juni 2025 · 15 min
He describes the Rusfertide result, which is partnered with Takeda and was presented in a plenary session at ASCO. Plus, he covers a UC announcement that JNJ made in March, and guides for when Protagonist will announce an obesity program.
-
ASCO 2025: Bicara Therapeutics' CEO Claire Mazumdar discusses the company's EGFR x TGF-β data in head and neck cancer, and compares and contrasts it with a closely watched competitor
2 juni 2025 · 9 min
She describes Bicara's data in HPV-negative HNSCC, and explains why the company is focused on this HVP-negative population specifically. Plus, how she believes the data compares to a closely watched competitor has a EGFR x LGR5 program.
-
ASCO 2025: Legend Biotech's CEO Ying Huang discusses new CARVYKTI data at ASCO as well as early stage data for emerging CAR-T targets against solid tumors
2 juni 2025 · 12 min
He describes long-term data for CARTITUDE-1 and a subset analysis from CARTITUDE-4. Plus, a DLL3 targeting armored CAR and a Claudin 18.2 program.
-
ASCO 2025: Arcus Biosciences' CEO Terry Rosen discusses data for the HIF-2a inhibitor Casdatifan in combination with Cabozantinib in kidney cancer
2 juni 2025 · 11 min
He describes the HIF-2a approach, and today's data release at ASCO, as well as why he believes Casdatifan can be best in class compared to one product that is already on the market.
-
ASCO 2025: Arvinas CEO John Houston discusses the phase 3 study result of the PROTAC Vepdegestrant in breast cancer, the first phase 3 readout of its kind for the field of protein degradation
2 juni 2025 · 11 min
He describes the trial's success in patients with ESR1 mutations, and discusses the steps ahead for both this program and the protein degradation field in general.
-
ASCO 2025: Novocure today announced positive overall survival data for its tumor treating fields technology in hard to treat pancreatic cancer
31 mei 2025 · 8 min
CEO Ashley Cordova describes the idea behind tumor treating fields, and walks us through today's pancreatic cancer data. Plus, how the company's launches are going in brain and lung cancers, and preparing to file in pancreatic later this year.
-
ASCO 2025: Gilead Sciences' Chairman & CEO Dan O'Day discusses today's 'practice changing' data for Trodelvy in 1L triple-negative breast cancer, cell therapy, and more from the oncology pipeline
31 mei 2025 · 15 min
He discusses the result of the ASCENT-04 study, which was in combination with Keytruda in PD-L1+ patients, and highlights data forthcoming at a future meeting for ASCENT-03 in PD-L1 negative patients. Plus, a brain cancer cell therapy program, Gilead's partnership with Arcus on TIGIT, and the company's deal appetite. Lees meer
-
ASCO 2025: Instil Bio CEO Bronson Crouch discusses the company's PD1 x VEGF, and shares a quick take on this morning's competitor news
30 mei 2025 · 10 min
He offers what he believes are learnings from this morning's data, and describes the data Instil's partner ImmuneOnco has derived for their asset to date. Plus, plans for future data later this year and getting a U.S. study up and running.
-
Pfizer Chairman & CEO Dr. Albert Bourla discusses the company's bets on cancer research, VEGF x PD1, #ASCO25 data, and hot button issues affecting the biopharma industry
30 mei 2025 · 19 min
Dr. Bourla looks back on Pfizers $43B acquisition of Seagen and the company's more recent license of a VEGF x PD1 bispecific. He highlights ASCO data for BRAFTOVI, vepdegestrant, and XTANDI. Plus, his thoughts on the hot button issues of China biotech and biopharma's public reputation. Lees meer
-
Piper Sandler Senior Analyst David Amsellem reacts to today's Teva Innovation & Strategy Day and shares his take on the company's pipeline
29 mei 2025 · 7 min
He gives his thoughts on the competitiveness of Teva's TL1A, and highlights other pipeline programs that biotech investors might look at. Plus, how the company is doing transitioning its investor base from generic drug focused investors to biotech.
-
At Teva's Innovation & Strategy Day in New York today, CEO Richard Francis discusses what 'Pivot to Growth' means for the company and offers takeaways from the presentation
29 mei 2025 · 8 min
He highlights Teva's improved financial position, its commercial prowess, and the pipeline assets to watch, including a TL1A that biotech investors have been watching closely.
-
Previewing top breast cancer and antibody-drug conjugate presentations to watch at this week's ASCO Annual Meeting with Dana-Farber's Paolo Tarantino
28 mei 2025 · 16 min
He describes key presentations for Enhertu, TRODELVY, immunotherapy medicines, and a couple key biomarkers to watch.
-
RBC Global Healthcare Conference: Desk Strategist Chris McCarthy shares how institutional investors have been affected by policy and macro factors, and how they have been positioning around catalysts
22 mei 2025 · 6 min
He describes how policy, macro, and events have been affecting trading in biotech stocks lately. Plus, his thoughts on the pull back of generalists from the sector.
-
RBC Global Healthcare Conference: Senior Biotech Analyst Luca Issi shares his thoughts on the current state of gene and cell therapy
22 mei 2025 · 9 min
He shares his overall thoughts on the biotech market, and discusses gene therapies, RNA editing, and cell therapy.
-
RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year
21 mei 2025 · 10 min
CEO Ram Aiyar describes Korro's 'OPERA' platform and explains why he thinks it is differentiated from others in the field. He previews the first data announcement that will happen later this year and discusses other work, including with the company's partner Novo Nordisk. Lees meer
-
RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead
21 mei 2025 · 12 min
CEO Sanjay Shukla describes the science behind tRNA synthetase biology and how aTyr is leveraging it against inflammatory and fibrotic diseases, especially pulmonary disease. He sets up the phase 3 for Efzofitimod in pulmonary sarcoidosis, and also pending data in systemic sclerosis. Lees meer
-
RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD
21 mei 2025 · 15 min
He describes where he sees AXPAXLI fitting into the treatment paradigm, and shares an update on the SOL-1 and SOL-R studies - including the rationale for recent changes to them. Plus an update on the NPDR indication.
-
RBC Global Healthcare Conference: RBC's Brian Abrahams shares his take on biotech and offers advice for companies on how to navigate these times of change
21 mei 2025 · 9 min
He describes some of the discussions he is having at the conference, discusses the difference between how large companies he covers are handling volatility vs smaller ones, and offers his take on the prospects for M&A.
-
RBC Global Healthcare Conference: Ahead of an important trial readout next month, Jeff Stein explains Cidara's unique approach to influenza and how it differs from vaccines
21 mei 2025 · 17 min
He describes the science behind Cidara's Cloudbreak Drug-Fc conjugates, which might have uniform efficacy regardless of how the flu changes each season. Plus, a preview of next month's readout, and how FDA discussions around this have been.
-
Stevenage, UK based TessellateBio recently signed a collaboration and licensing deal with Boehringer Ingelheim targeting tumors dependent on alternative lengthening of telomeres (ALT) for their growth
20 mei 2025 · 10 min
CEO Andree Blaukat describes TessellateBio's focus on synthetic lethality and the science behind this lead area they have partnered with Boehring Ingelheim on, which seeks to interrupt some cancers' ability to harness telomeres to continuously replicate. The deal is potentially work in excess of €500 million. Plus addition programs, including one targeting SKP2. Lees meer
-
Cambridge, UK based Maxion Therapeutics raised a $72M series A in March to advance its KnotBody programs - which combine the benefits of knottins and antibodies and can target ion channels and GPCRs
16 mei 2025 · 14 min
CEO Arndt Schottelius describes the rationale behind the KnotBody platform and the company's future plans to develop them against things like inflammatory diseases such as atopic dermatitis and inflammatory bowel disease.
-
ASGCT 2025: HuidaGene presented preclinical and early clinical data for its CRISPR Cas12 based program for DMD in a Presidential Symposium talk
16 mei 2025 · 9 min
CEO Alvin Luk and CTO TJ Cradick explain how the company's Cas12 and 13 programs are different than Cas9, and they discuss the DMD presentation and how this program differs from the current microdystrophin product that is on the market. Plus, RNA editing programs targeting neovascular age-related macular degeneration and MECP2 Duplication Syndrome (MDS), and a DNA program targeting ALS. Lees meer
-
ASGCT 2025: Dyno Therapeutics CEO Eric Kelsic discusses the latest in capsids for CNS, ophthalmology, and neuromuscular conditions
16 mei 2025 · 11 min
He talks about new capsids Dyno announced at this years' conference and the science behind getting them to specific places in the body. Plus, the company's new 'Frontiers Program' and a Genetic Agency Technology Conference coming up in November.
-
ASGCT 2025: Physicians and scientists raced to make a bespoke gene editing therapy for an infant who urgently needed one in months - a first hand account, and what this means for drug development
15 mei 2025 · 17 min
As published in NEJM today, UPenn's Kiran Musunuru describes how the team used base editing in a matter of months to treat an infant with CPS1 deficiently, and his thoughts on what the learnings of this case are for drug development.
-
ASGCT 2025: Coave Therapeutics presented a late breaker showing a positive profile for its cerebrospinal fluid administered ligand-engineered AAV2-based capsid
15 mei 2025 · 10 min
CEO Rodolphe Clerval walks us through Coave's "ALIGATER' ligand technology and describes the importance of the cerebrospinal administered program. Plus, comments on the company's IV program for CNS conditions, and a recent €32 million series A.
-
Cambridge, UK based Alchemab Therapeutics last week signed a second collaboration with Eli Lilly worth up to $415M to license its IND ready program for ALS and other neurodegenerative diseases
15 mei 2025 · 12 min
CEO Jane Osbourn describes Alchemab's platform, which looks for people who are resilient to disease and then sequences them to understand why, and discusses this week's deal and the company's prior one with Lilly as well.
-
ASGCT 2025: The Co-Founder of ProQR discusses the company's Axiomer RNA base editing technology - which will see a CTA filed this quarter and data by the end of the year
15 mei 2025 · 7 min
ProQR Co-Founder & CSO Gerard Platenburg describes the company's RNA editing platform and the journey he has seen this field go through over time. Plus, updates on programs for cholestatic diseases, Rhett Syndrome, and MASH.
-
ASGCT 2025: Capsida Biotherapeutics is using its expertise in capsid design to develop gene therapies that are tissue specific, and in the case of the CNS, can be delivered via IV and crosses the BBB
14 mei 2025 · 10 min
CEO Peter Anastasiou describes the importance of capsid design and how Caspida is developing its own gene therapies for CNS conditions. A first program recently had its IND cleared.
-
ASGCT 2025: The co-founders of Circio describe the properties they believe make circular RNA a better, more durable medium for use in gene and cell therapies
14 mei 2025 · 9 min
CEO Erik Wiklund and CTO Thomas Hansen describe what circular RNA is, and explain their groundbreaking work where they discovered circular RNA in humans over a decade ago. They discuss potential use cases, including using it for in-vivo CAR-T, something that has been talked about a lot at this year's conference. Lees meer
-
Gene therapies expert TJ Cradick previews what to watch for at the 2025 ASGCT Annual Meeting in New Orleans
13 mei 2025 · 12 min
He discusses the clinical programs, delivery vehicle advances, and safety improvements to watch for this year as the field of cell and gene therapies progresses.
-
Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized
13 mei 2025 · 17 min
Inductive Bio raised a $25M series A last week to continue its work utilizing AI to help drug developers in discovery understand a small molecule's ADMET properties before it is synthesized.
-
NewLimit raised a $130M series B round last week to advance its work using epigenetic reprogramming to improve cell function and thus aim to extend longevity
12 mei 2025 · 20 min
Co-Founder & President Jacob Kimmel and Head of Operations Cathy O'Hare describe the scientific approach and how it benefits from the crossroads of genomics and machine learning. Plus, which indications the company plans to start out in clinically.
-
Biotech investor Christoph Broja of EQT Life Sciences discusses biotech in Europe and highlights portfolio companies Tubulis, Agomab Therapeutics, and PanTera
9 mei 2025 · 19 min
He describes the current environment for life sciences in Europe and how far it has come over the last ten years. Plus, his thoughts on the value of being local for uncovering opportunities, and the state of the capital markets.
-
With a phase 3 trial for its PRAME cell therapy underway and a data update coming up at ASCO, Immatics is pushing to be a leader in TCR based cell therapies and T-cell engagers
9 mei 2025 · 13 min
CEO Harpreet Singh joins us from the company's office in Munich, Germany, where he describes the founding of the company and previews catalysts to watch for over the year ahead.
-
Mosaic Therapeutics, which uses advanced computational methods and next-generation cancer models to design novel combination therapies, licensed an ERK1/2 and MDM2 inhibitor from Astex Pharmaceuticals
9 mei 2025 · 7 min
Interim CEO Magda Jonikas describes Mosaic's platform and the rationale behind these two targets the company has licensed in.
-
Cambridge, UK based Epitopia is helping Merck (MSD) discover tumor associated antigens from the non-coding regions of the genome using its CryptoMap platform
9 mei 2025 · 10 min
CEO Alan Rigby talks about the work Epitopia does finding "Crypotgen" antigens for its own off-the-shelf cancer vaccines, and discusses what was appealing to Merck about the partnership.
-
Munich based Tubulis is working on ADCs that it believes are more durable, potent, and homogenous than others on the market currently - it has signed partnerships with Gilead and Bristol
8 mei 2025 · 17 min
Co-Founder and CEO Dominik Schumacher describes what he thinks can be improved on from the current generation of antibody-drug conjugates, and the science behind how Tubilis is designing its ADCs differently. He highlights the company's clinical Napi2b and 5T4 programs. Lees meer
-
As the field builds on the initial success of PARP inhibitors, Artios Pharma is working on the next generation of DNA Damage Response (DDR)-based therapies - it just had clinical data on one at AACR
8 mei 2025 · 20 min
CEO Niall Martin walks us through the current state of this corner of drug development, and then highlights data presented at AACR last week for its ATR kinase inhibitor. As he describes, patient selection for these therapies can make a big difference. Lees meer
-
Munich based ITM Radiopharma is progressing towards a first NDA in the U.S. with a robust pipeline behind it - all the while making investments in isotope manufacturing that has slowed others
8 mei 2025 · 21 min
CEO Andrew Cavey describes how ITM has been investing to avoid the shortages others have experienced, and explains how the supply chain works for radiopharmaceuticals. He walks us through the science behind these medicines before highlighting ITM's pipeline. Lees meer
-
Munich based Ethris is developing a proprietary mRNA and lipid nanoparticle combination that is stable and allows for nasal administration or to be inhaled via nebulization
7 mei 2025 · 16 min
CEO Carsten Rudolph and CMO Thomas Langenickel describe the technology, which can be spray dried and shipped in a dry powder formulation, and also the clinical experience so far on the lead program in asthma.
-
Swiss Biotech Day: Geneva based Light Chain Bioscience is developing bi-specifics that integrate two light chains into its structure with the goal of having a more native format
6 mei 2025 · 8 min
CEO Nicolas Fischer describes the rationale of designing bi-specifics this way, and walks us through the company's programs, which mostly have a CD47 or CD28 backbone.
-
Swiss Biotech Day: Milan based Genenta Science recently raised €20 million from a government investment fund as it takes its cell therapy into the clinic in renal cell carcinoma
6 mei 2025 · 9 min
Co-Founder and CEO Pierluigi Paracchi describes the terms of the convertible bond raise, which gives the investor, ENEA Tech and Biomedical, the opporutnity to convert to equity in three years. He also provides an update on the progress of dosing renal cell carcinoma patients in the clinic, and what we can expect from the trial throughout the rest of the year. Lees meer
-
Swiss Biotech Day: Lausanne based Tigen Pharma is building out decentralized CAR-T manufacturing capabilities with global partners - it already has a program with Memorial Sloan Kettering
6 mei 2025 · 10 min
Chairman & CEO Emmanuel Savioz describes the benefits of decentralized manufacturing that is at or near the site of treatment. He highlights an armored-CAR AML program the company has with MSK in New York, and discusses Tigen's non-viral platform for NHL and multiple myeloma. Lees meer